Verily has raised a $300 million investment round to accelerate its efforts in artificial intelligence and precision medicine as it leaves Alphabet.
The large round was led by Series
Verily has transitioned its legal structure from an LLC to a corporation and changed its name to Verily Health.
“At Alphabet, we applaud Verily’s tenacity in leveraging technology to address long-standing challenges in the healthcare industry,” Ruth Porat, president and chief investment officer of Alphabet and Google, said in a statement. “Alphabet’s continued involvement, along with the addition of new investors, will enable Verily to further scale its business, improve patient outcomes and reduce the cost of healthcare delivery through its AI health platform.”
UCHealth and the University of Colorado Anschutz College are also investors, the company said. Verily has developed deep relationships with health systems and academic medical institutions through technology and research collaborations announced last October.
“Partnering with Verily to bring a shared data framework to healthcare data and make it AI-enabled creates a generational opportunity for UCHealth and healthcare,” said Richard Zane, MD, UCHealth’s chief medical and innovation officer, in a statement. “This collaboration will help unlock the long-promised potential of personalized care to benefit patients, and ultimately all patients. This will save lives, and we are eager to get started.”
Founded in 2015, Verily began as a Google X moonshot and evolved into a data platform and AI company focused on precision medicine as a subsidiary of Alphabet. Verily, once a sister company of Google, has increased its focus on digital precision medicine and clinical research platforms over the past three years.
The company has developed Verily Pre, a precision medicine platform that serves as the data and technology foundation for all Verily solutions. Last fall, the company launched a free consumer health app called Verily Me that provides patients with personalized care recommendations based on their health data. The app aims to identify gaps in care and provide customized health recommendations, and includes an AI agent called Violet that answers questions about users’ health records, Verily executives said.
“From research to care, our customers need solutions that combine AI with the highest clinical and scientific rigor to deliver the next generation of healthcare – something as accurate as it is personal. Series X Capital, Alphabet, UC Health, the University of Colorado Anschutz and our many investors will be great partners in this healthcare transformation,” Stephen Gillette, chairman and CEO of Verily, said in a statement.
Verily focuses on building and extending AI models and agents for research and care workflows. On the clinical side, we developed LightPath, a chronic disease and weight loss management program with grants from employers, payers, and pharmacy benefit managers. We have also built innovations for public health, such as Cytline, a sewage-based epidemiology for early detection of infectious diseases.
Executives said the $300 million investment will advance the company’s efforts in AI and precision medicine around the world, including expanding the capabilities of Verily Pre and Verily Me, launching new agents, and driving new commercial opportunities.
“This is already the NIH All of Us “This means further investment in pre-data solutions such as Workbench, which underpins the Research program and supports more than 21,500 researchers around the world. This means expanding the capabilities of Sightline, an essential solution for national monitoring of infectious diseases, and growing Lightpath to help more people manage the everyday realities of diabetes and hypertension with tailored care and always-on support,” Gillette said in a blog post.
“On the clinical research front, this means further expanding Viewpoint Evidence tools for conducting real-world research with recontactable participant registries, refineries for medical data harmonization, and workbenches for multimodal data analysis,” Gillette wrote.
Verily, a 2025 Furious 50 company, is also expanding its commercial partnerships. In collaboration with Samsung, the companies are integrating Galaxy Watch 8 sensor data into Verily’s Pre platform to support real-world research and population health monitoring. Verily is also partnering with Salesforce to integrate its precision medicine platform with Agentforce Health to “help providers make sense of messy health data,” Gillette said in a blog post.
Verily is also working with Nvidia to integrate its AI technology stack into the Pre platform to accelerate research and analysis and accelerate the development of AI agents and models for clinical care and research.
Gillette acknowledged in a blog post that Verily’s evolution as a business “has not been a linear journey.”
Fierce MedTech’s Connor Hale reports that in early 2023, Verily began exiting various areas of the healthcare space where it had once worked to better align its bets to become a more profitable company.
Verily, once known for working on everything from smart contact lenses and wearable sensors to surgical robots and virtual clinics, has shifted to a slightly more focused and stated goal of focusing on products that enable medical precision.
“Over the past few years, we’ve gone through a deliberate and, frankly, sometimes difficult transformation. We’ve had to make tough decisions about where to strengthen and where to let go. But that work has given us the increased focus we need to launch innovative solutions like the Verily Pre platform,” Gillette wrote in a blog post.
